An International Study on Pediatric Patients With Rare Tumors.
NCT07072143 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6250
Last updated 2025-07-18
Summary
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
Conditions
- Paraganglioma/ Phaeochromocytoma
- Melanoma and Other Malignant Neoplasms of Skin
- Gastrointestinal Stromal Tumor (GIST)
- Adrenocortical Tumor
- Pancreatic Tumors
- Esthesioneuroblastoma, Olfactory
- Mesothelioma
- Nasopharyngeal Carcinoma (NPC)
- NUT Carcinoma
- Pleuropulmonary Blastoma
- Salivary Gland Tumors
- Thymic Tumors
- Thyroid Carcinoma
- Appendiceal Cancers
Sponsors & Collaborators
-
St. Anna Children's Hospital, Vienna
collaborator UNKNOWN -
Children's Hospital Zagreb
collaborator OTHER -
Centre Hospitalier Universitaire de La Réunion, FRANCE
collaborator UNKNOWN -
Klinikum Dortmund
collaborator UNKNOWN -
University Children's Hospital Tuebingen
collaborator OTHER -
Hellenic Oncology Research Group
collaborator OTHER -
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
collaborator OTHER -
Kaplan Medical Center, Rehovot, Israel
collaborator UNKNOWN -
Vilnius University hospital Santaros klinikos, Vilnius, Lithuania
collaborator UNKNOWN -
University of Skopje
collaborator OTHER -
Gdansk Medical University (Poland)
collaborator UNKNOWN -
Centro Hospitalar do Porto
collaborator OTHER -
Bucharest Emergency Hospital
collaborator OTHER -
Institute for Oncology and Radiology Serbia, Belgrade
collaborator UNKNOWN -
University Hospital Bratislava
collaborator OTHER -
University Medical Centre Ljubljana
collaborator OTHER -
University of Bilbao
collaborator UNKNOWN -
Göteborg University
collaborator OTHER -
University Hospital, Paris
collaborator OTHER -
Azienda Ospedaliera di Padova
lead OTHER
Principal Investigators
-
Gianni Bisogno, MD · Azienda Ospedale Università Padova - Italy
Eligibility
- Min Age
- 0 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-25
- Primary Completion
- 2049-01-06
- Completion
- 2049-06-06
Countries
- Italy
Study Locations
More Related Trials
-
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
NCT00346164 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
NCT05302921 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
NCT01962103 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
International Pediatric Adrenocortical Tumor Registry
NCT00700414 ·Status: RECRUITING
-
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
NCT01802814 ·Status: COMPLETED ·Phase: PHASE3
-
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
NCT00002802 ·Status: COMPLETED ·Phase: PHASE3
-
High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
NCT00180791 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
NCT03628131 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
NCT00024284 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours
NCT02303028 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
NCT02638428 ·Status: UNKNOWN ·Phase: PHASE2
-
Role of Tumoral Biomarker B3 Adrenergic Receptor in Paediatric Solid Tumours
NCT06312150 ·Status: RECRUITING ·Phase: NA
-
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT02303821 ·Status: COMPLETED ·Phase: PHASE1
-
Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors
NCT03585465 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
NCT02748135 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma
NCT00002941 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
NCT04730349 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
NCT07334301 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma
NCT00317408 ·Status: UNKNOWN ·Phase: NA
-
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
NCT05304585 ·Status: RECRUITING ·Phase: PHASE3
-
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
NCT00101205 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
NCT00025441 ·Status: COMPLETED ·Phase: PHASE2
-
Paediatric Hepatic International Tumour Trial
NCT03017326 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
NCT01700946 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma
NCT02025881 ·Status: TERMINATED ·Phase: PHASE1/PHASE2